Compare Stocks: CLNN, SIGA, ZNTL, and CRDL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLNN Clene	$4.29 -2.1%	$4.61	$3.25 ▼ $13.50	$55.73M	0.95	233,151 shs	75,246 shs
CRDL Cardiol Therapeutics	$1.77 -6.3%	$1.69	$0.88 ▼ $2.34	$205.64M	0.79	754,422 shs	2.00 million shs
SIGA Siga Technologies	$3.17 -2.8%	$3.15	$2.83 ▼ $9.29	$227.76M	0.97	611,154 shs	434,997 shs
ZNTL Zentalis Pharmaceuticals	$2.87 -6.8%	$4.07	$1.21 ▼ $6.95	$205.69M	1.85	1.55 million shs	1.45 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLNN Clene	-3.52%	+8.96%	+1.39%	-23.69%	-31.56%
CRDL Cardiol Therapeutics	+1.61%	+2.16%	+1.61%	+83.50%	+68.75%
SIGA Siga Technologies	+3.16%	+9.40%	+7.24%	-24.54%	-65.21%
ZNTL Zentalis Pharmaceuticals	+1.65%	-1.60%	-19.58%	-22.42%	+102.63%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLNN Clene	$4.29 -2.1%	$4.61	$3.25 ▼ $13.50	$55.73M	0.95	233,151 shs	75,246 shs
CRDL Cardiol Therapeutics	$1.77 -6.3%	$1.69	$0.88 ▼ $2.34	$205.64M	0.79	754,422 shs	2.00 million shs
SIGA Siga Technologies	$3.17 -2.8%	$3.15	$2.83 ▼ $9.29	$227.76M	0.97	611,154 shs	434,997 shs
ZNTL Zentalis Pharmaceuticals	$2.87 -6.8%	$4.07	$1.21 ▼ $6.95	$205.69M	1.85	1.55 million shs	1.45 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLNN Clene	-3.52%	+8.96%	+1.39%	-23.69%	-31.56%
CRDL Cardiol Therapeutics	+1.61%	+2.16%	+1.61%	+83.50%	+68.75%
SIGA Siga Technologies	+3.16%	+9.40%	+7.24%	-24.54%	-65.21%
ZNTL Zentalis Pharmaceuticals	+1.65%	-1.60%	-19.58%	-22.42%	+102.63%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLNN Clene	2.71	Moderate Buy	$34.00	683.41% Upside
CRDL Cardiol Therapeutics	2.50	Moderate Buy	$10.00	466.57% Upside
SIGA Siga Technologies	1.00	Sell	N/A	N/A
ZNTL Zentalis Pharmaceuticals	2.40	Hold	$6.75	135.93% Upside

Current Analyst Ratings Breakdown

Latest CLNN, SIGA, ZNTL, and CRDL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$9.00
9/21/2026	CRDL Cardiol Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/16/2026	ZNTL Zentalis Pharmaceuticals	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
9/10/2026	CLNN Clene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	CLNN Clene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/26/2026	CRDL Cardiol Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
8/17/2026	CLNN Clene	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	CRDL Cardiol Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$8.00 ➝ $10.00
8/14/2026	CLNN Clene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	SIGA Siga Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
7/30/2026	CLNN Clene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLNN Clene	$200K	281.88	N/A	N/A	($1.62) per share	-2.68
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	$0.11 per share	N/A
SIGA Siga Technologies	$94.57M	2.41	$0.33 per share	9.49	$2.78 per share	1.14
ZNTL Zentalis Pharmaceuticals	$67.43M	3.04	N/A	N/A	$2.99 per share	0.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLNN Clene	-$26.17M	-$3.50	N/A	N/A	N/A	-20,063.96%	N/A	-137.04%	11/12/2026 (Estimated)
CRDL Cardiol Therapeutics	-$24.20M	-$0.25	N/A	N/A	N/A	N/A	-180.44%	-140.28%	11/12/2026 (Estimated)
SIGA Siga Technologies	$23.28M	-$0.05	N/A	N/A	N/A	-5.19%	-1.55%	-1.32%	11/5/2026 (Estimated)
ZNTL Zentalis Pharmaceuticals	-$137.06M	-$1.95	N/A	N/A	N/A	N/A	-70.18%	-51.46%	11/10/2026 (Estimated)

Latest CLNN, SIGA, ZNTL, and CRDL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	CLNN Clene	-$0.3680	-$1.08	-$0.7120	-$1.08	$0.06 million	$0.09 million
8/13/2026	Q2 2026	CRDL Cardiol Therapeutics	-$0.09	-$0.04	+$0.05	-$0.04	N/A	N/A
8/6/2026	Q2 2026	SIGA Siga Technologies	N/A	$0.17	N/A	$0.17	N/A	$41.00 million
8/6/2026	Q2 2026	ZNTL Zentalis Pharmaceuticals	-$0.49	-$0.59	-$0.10	-$0.59	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLNN Clene	N/A	N/A	N/A	N/A	N/A
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLNN Clene	N/A	3.07	3.07
CRDL Cardiol Therapeutics	N/A	5.55	5.55
SIGA Siga Technologies	N/A	21.72	16.48
ZNTL Zentalis Pharmaceuticals	N/A	4.82	4.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLNN Clene	23.28%
CRDL Cardiol Therapeutics	12.49%
SIGA Siga Technologies	55.40%
ZNTL Zentalis Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
CLNN Clene	28.30%
CRDL Cardiol Therapeutics	5.25%
SIGA Siga Technologies	2.73%
ZNTL Zentalis Pharmaceuticals	3.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLNN Clene	79	12.99 million	9.32 million	No Data
CRDL Cardiol Therapeutics	18	116.18 million	110.08 million	Not Optionable
SIGA Siga Technologies	49	71.85 million	69.89 million	Optionable
ZNTL Zentalis Pharmaceuticals	106	71.67 million	68.95 million	Optionable

CLNN, SIGA, ZNTL, and CRDL Headlines

Recent News About These Companies

Financial Contrast: Harmony Biosciences (NASDAQ:HRMY) vs. Zentalis Pharmaceuticals (NASDAQ:ZNTL)

September 22 at 6:16 AM | americanbankingnews.com

Zentalis Pharmaceuticals stock falls after public offering pricing and trades below recent highs

September 18, 2026 | ad-hoc-news.deA

William Blair Initiates Coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL)

September 16, 2026 | marketbeat.com

Comparing Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Sol-Gel Technologies (NASDAQ:SLGL)

September 16, 2026 | americanbankingnews.com

William Blair Starts Zentalis Pharmaceuticals (ZNTL) at Outperform

September 16, 2026 | streetinsider.com

Zentalis Pharmaceuticals, Inc. (ZNTL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 14, 2026 | seekingalpha.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Rating of "Hold" by Analysts

September 10, 2026 | marketbeat.com

BlackRock Inc. Invests $18.20 Million in Zentalis Pharmaceuticals, Inc. $ZNTL

September 4, 2026 | marketbeat.com

Zentalis to present at Wells Fargo, Morgan Stanley events

September 2, 2026 | msn.com

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

September 2, 2026 | globenewswire.com

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 1, 2026 | globenewswire.com

Zentalis Pharmaceuticals: Data Due H1 '27 Will Clarify Prospects Of Azenosertib

August 31, 2026 | seekingalpha.com

Connor Clark & Lunn Investment Management Ltd. Makes New Investment in Zentalis Pharmaceuticals, Inc. $ZNTL

August 29, 2026 | marketbeat.com

Primecap Management Co. CA Takes $4.64 Million Position in Zentalis Pharmaceuticals, Inc. $ZNTL

August 27, 2026 | marketbeat.com

652,750 Shares in Zentalis Pharmaceuticals, Inc. $ZNTL Acquired by ADAR1 Capital Management LLC

August 26, 2026 | marketbeat.com

3,947,913 Shares in Zentalis Pharmaceuticals, Inc. $ZNTL Acquired by 5AM Venture Management LLC

August 26, 2026 | marketbeat.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Group Walters Acquires 4,335,000 Shares

August 20, 2026 | insidertrades.com

Zentalis Pharma closes $92.6 million public offering

August 19, 2026 | thepharmaletter.comT

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

August 17, 2026 | markets.businessinsider.com

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

August 17, 2026 | globenewswire.com

Zentalis Pharmaceuticals Prices $80.5 Million Offering to Fund Clinical Pipeline

August 14, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLNN, SIGA, ZNTL, and CRDL Company Descriptions

Clene NASDAQ:CLNN

$4.29 -0.09 (-2.05%)

Closing price 04:00 PM Eastern

Extended Trading

$4.32 +0.04 (+0.82%)

As of 04:10 PM Eastern

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Cardiol Therapeutics NASDAQ:CRDL

$1.77 -0.12 (-6.35%)

Closing price 04:00 PM Eastern

Extended Trading

$1.76 -0.01 (-0.56%)

As of 06:18 PM Eastern

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Siga Technologies NASDAQ:SIGA

$3.17 -0.09 (-2.76%)

Closing price 04:00 PM Eastern

Extended Trading

$3.17 0.00 (0.00%)

As of 06:15 PM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

Zentalis Pharmaceuticals NASDAQ:ZNTL

$2.87 -0.21 (-6.82%)

Closing price 04:00 PM Eastern

Extended Trading

$2.93 +0.06 (+2.09%)

As of 06:09 PM Eastern

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLNN, SIGA, ZNTL, and CRDL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLNN, SIGA, ZNTL, and CRDL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLNN, SIGA, ZNTL, and CRDL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLNN, SIGA, ZNTL, and CRDL Company Descriptions

Clene NASDAQ:CLNN

Cardiol Therapeutics NASDAQ:CRDL

Siga Technologies NASDAQ:SIGA

Zentalis Pharmaceuticals NASDAQ:ZNTL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLNN, SIGA, ZNTL, and CRDL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLNN, SIGA, ZNTL, and CRDL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLNN, SIGA, ZNTL, and CRDL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLNN, SIGA, ZNTL, and CRDL Company Descriptions

Clene NASDAQ:CLNN

Cardiol Therapeutics NASDAQ:CRDL

Siga Technologies NASDAQ:SIGA

Zentalis Pharmaceuticals NASDAQ:ZNTL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools